Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP et al. · The New England journal of medicine · PMID 37366315
Study summary
Main finding
A placebo-controlled trial reported greater weight reduction with retatrutide over 48 weeks in adults meeting defined BMI and health criteria. Safety was also assessed.
A randomized, double-blind, placebo-controlled trial followed 338 adults for 48 weeks. Participants met specified BMI and health criteria; the study used a controlled investigational formulation.
What the researchers measured
Percentage change in body weight at 24 weeks was the primary outcome. Other outcomes included weight change at 48 weeks, the proportion reaching weight-loss thresholds, and adverse events.
How to read this evidence
The paper includes research in people. Its comparison groups, participant selection, follow-up, and measured outcomes determine how far the findings can be applied. The label alone does not establish efficacy or safety.
Results in context
Weight changes were group averages, not predictions for an individual. Gastrointestinal adverse events were common and generally mild to moderate. Dose-related heart-rate increases peaked at 24 weeks and then declined; weight change alone does not describe the safety findings.
What this does not establish
This selected 2023 trial concerns a controlled investigational formulation and population. It does not validate a retail research vial or establish its safety.
Publication & source
Why this paper is included
The compound is a named subject of the publication title.